Skip to content

Generate Biomedicines

US · GENB #2875 by market cap Listed 2026
9.54 -0.83 -8.00%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:32

Recent news

  • Rating change
    H.C. Wainwright Initiates Generate Biomedicines(GENB.US) With Buy Rating, Announces Target Price $16
    Market Newswire · 2026/4/13
  • Rating change
    Guggenheim Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/6/25
  • H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/11/13
  • Rating change
    H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $25
    Market Newswire · 2026/5/8
  • Rating change
    Analysts Offer Insights on NA Companies: Yesway Inc Class A (YSWY), Generate Biomedicines, Inc. (GENB) and SK Hynix Inc. Sponsored GDR (OtherHXSCL)
    TipRanks · 2026/6/25
  • Earnings Flash (GENB) Generate Biomedicines Posts Q3 Net Loss $0.68 a Share, Vs. FactSet Est of $0.56 Loss
    MT Newswires · 2026/11/12
  • Rating change
    Guggenheim Reaffirms Their Buy Rating on Generate Biomedicines, Inc. (GENB)
    TipRanks · 2026/6/15
  • Rating change
    H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $30
    Market Newswire · 2026/8/28
  • Rating change
    Analysts Offer Insights on NA Companies: Guidewire (GWRE) and Generate Biomedicines, Inc. (GENB)
    TipRanks · 2026/9/9
  • Rating change
    Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24
    Market Newswire · 2026/8/7
  • Rating change
    Morgan Stanley Sticks to Its Buy Rating for Generate Biomedicines, Inc. (GENB)
    TipRanks · 2026/8/17
  • Rating change
    Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $22
    Market Newswire · 2026/8/17
  • Rating change
    H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $25
    Market Newswire · 2026/8/7
  • Rating change
    Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)
    TipRanks · 2026/5/8
  • Earnings Flash (GENB) Generate Biomedicines, Inc. Reports Q3 Collaboration Revenue $4.2M
    MT Newswires · 2026/11/12
  • Rating change
    Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $26
    Market Newswire · 2026/10/14
  • Rating change
    Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $22
    Market Newswire · 2026/5/14
  • Piper Sandler Keeps Their Buy Rating on Generate Biomedicines, Inc. (GENB)
    TipRanks · 2026/10/14
  • Analysts Are Bullish on Top NA Stocks: Generate Biomedicines, Inc. (GENB), Netskope, Inc. (NTSK)
    TipRanks · 2026/10/2
  • Rating change
    Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $26
    Market Newswire · 2026/10/2
  • Rating change
    Goldman Sachs Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $26
    Market Newswire · 2026/4/11
  • H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/10/30
  • Rating change
    Goldman Sachs Initiates Generate Biomedicines(GENB.US) With Buy Rating, Announces Target Price $26
    Market Newswire · 2026/3/25
  • H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/10/15
  • H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/10/5

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:32:29 · For reference only, not investment advice and not tailored to your situation.

Generate Biomedicines discussion 0 comments

Add a comment